logo
Twitter
Discord
Email
logo
logo
89bio, Inc.NASDAQ - ETNB
Reports
Search reports
Name
Reporting Date
Filing Date
2024-09-30 10-Q2024-09-302024-11-07
2024-06-30 10-Q2024-06-302024-08-05
2024-03-31 10-Q2024-03-312024-05-09
2023-12-31 10-K2023-12-312024-03-01
2023-09-30 10-Q2023-09-302023-11-09
2023-06-30 10-Q2023-06-302023-08-09
2023-03-31 10-Q2023-03-312023-05-08
2022-12-31 10-K2022-12-312023-03-15
2022-09-30 10-Q2022-09-302022-11-10
2022-06-30 10-Q2022-06-302022-08-11
2022-03-31 10-Q2022-03-312022-05-12
2021-12-31 10-K2021-12-312022-03-24
2021-09-30 10-Q2021-09-302021-11-12
2021-06-30 10-Q2021-06-302021-08-13
2021-03-31 10-Q2021-03-312021-05-14
2020-12-31 10-K2020-12-312021-03-25
2020-09-30 10-Q2020-09-302020-11-13
2020-06-30 10-Q2020-06-302020-08-13
2020-03-31 10-Q2020-03-312020-05-13
2019-12-31 10-K2019-12-312020-03-18
1
2
20 / page
About
Name
89bio, Inc.
Overview
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
Show More
CEO
Mr. Rohan Palekar
Industry
Biotechnology
Exchange
NASDAQ
Listing Date
2019-11-11
Address
142 Sansome Street, Second Floor, San Francisco, CA, 94104, United States
Tel
415-432-9270
Website
https://www.89bio.com